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Abstract 
Background: Malaria was eliminated in Spain in 1964. Since then, more than 10,000 cases of malaria have been 
reported, mostly in travellers and migrants, making it the most frequently imported disease into this country. In order 
to improve knowledge on imported malaria cases characteristics, the two main malaria data sources were assessed: 
the national surveillance system and the hospital discharge database (CMBD).
Methods: Observational study using prospectively gathered surveillance data and CMBD records between 2002 
and 2015. The average number of hospitalizations per year was calculated to assess temporal patterns. Socio‑demo‑
graphic, clinical and travel background information were analysed. Bivariate and multivariable statistical methods 
were employed to evaluate hospitalization risk, fatal outcome, continent of infection and chemoprophylaxis failure 
and their association with different factors.
Results: A total of 9513 malaria hospital discharges and 7421 reported malaria cases were identified. The number of 
reported cases was below the number of hospitalizations during the whole study period, with a steady increase trend 
in both databases since 2008. Males aged 25–44 were the most represented in both data sources. Most frequent 
related co‑diagnoses were anaemia (20.2%) and thrombocytopaenia (15.4%). The risks of fatal outcome increased 
with age and were associated with the parasite species (Plasmodium falciparum). The main place of infection was 
Africa (88.9%), particularly Equatorial Guinea (33.2%). Most reported cases were visiting friends and relatives (VFRs) 
and immigrants (70.2%). A significant increased likelihood of hospitalization was observed for children under 10 years 
(aOR:2.7; 95% CI 1.9–3.9), those infected by Plasmodium vivax (4.3; 95% CI 2.1–8.7) and travellers VFRs (1.4; 95% CI 
1.1–1.7). Only 4% of cases reported a correct regime of chemoprophylaxis. Being male, over 15 years, VFRs, migrant 
and born in an endemic country were associated to increased risk of failure in preventive chemotherapy.
Conclusions: The joint analysis of two data sources allowed for better characterization of imported malaria profile 
in Spain. Despite the availability of highly effective preventive measures, the preventable burden from malaria is high 
in Spain. Pre‑travel advice and appropriately delivered preventive messages needs to be improved, particularly in 
migrants and VFRs.
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Background
According to the World Health Organization (WHO), 
between 2000 and 2015 there has been a 37% global 
decrease in malaria incidence and a 60% decrease in 
global mortality rates [1]. Meantime, increasing travel to 
endemic areas in recent decades in association with the 
significant influx of immigrants from malaria-endemic 
countries has brought a steady increase in the number of 
imported cases in non-endemic countries [2].
Malaria poses a serious health hazard for travellers to 
areas of endemicity. Imported malaria refers to infec-
tions acquired outside and brought into a national terri-
tory [3]. Imported cases to non-endemic countries often 
result in delays in diagnosis, are expensive to treat, and 
can sometimes cause secondary local transmission [4]. In 
2016, the European Region was the first in the world to 
have achieved interruption of indigenous malaria trans-
mission. Still, malaria is the imported disease with the 
highest number of notifications in Europe [5]. It has been 
estimated that every year 10–15 million international 
travellers from Europe visit malaria endemic areas and 
12,000–15,000 cases of malaria are imported into the EU, 
with an average fatality rate of 0.4–3% [6]. The European 
Centre for Disease Prevention and Control (ECDC) coor-
dinates this disease surveillance in the European Union 
(EU) and the member countries of the European Free 
Trade Association (EFTA). In 2015, the largest number 
of confirmed cases in this region was notified by France, 
followed by the UK and Spain (2500, 1397 and 706 cases, 
respectively) [7].
Spain was declared free of malaria in 1964. In the last 
decades, notified malaria infections have been mostly 
imported [8, 9]. Cases by autochthonous transmis-
sion have been scarce, and mainly related to health care 
(transfusion, transplants, parenteral or nosocomial), or 
vertical transmission. The cases of airport malaria have 
been anecdotal, and only 2 recent cases of malaria intro-
duced by Plasmodium vivax have been documented [10]. 
Although there is a wide distribution of the potential vec-
tor of this species, it is considered that the current risk 
of introduced malaria is low [8]. Confirmed cases are 
monitored through the National Network of Epidemio-
logical Surveillance (RENAVE in Spanish, Royal Decree 
2210/1995) [11]. The last update of the malaria surveil-
lance protocol was carried out in 2013 [12]. Other alter-
native source of information is the Centralized Hospital 
Discharge Database (CMBD in Spanish).
Reports have shown that knowledge on infectious 
disease prevention among departing travellers and the 
adherence of travellers to WHO and Centers for Disease 
Control and Prevention (CDC) recommendations is far 
from optimal [13]. In Spain, pre-travel consultation is 
voluntary (except for the yellow fever vaccination, which 
is mandatory at the entrance of several countries). Pre-
ventive measures and chemoprophylaxis against malaria 
follow the WHO recommendations, and depend on the 
travel destination, the duration of potential exposure, 
parasite resistance pattern, level and seasonality of trans-
mission, age and pregnancy [14]. In order to improve 
knowledge on malaria imported cases characteristics, the 
epidemiological and clinical characteristics of patients 
diagnosed with malaria within the CMBD and the 
RENAVE databases were assessed. The hospitalization 
risk factors and the possible association between malaria 
chemoprophylaxis intake and gender, age or travel rea-
son, among other factors, were also explored.
Methods
Data source
An epidemiological study using the CMBD and the 
RENAVE database for the time period January 1st, 2002 
to December 31st, 2015 was performed.
CMBD
The CMBD database receives notification from around 
98% of the public hospitals in Spain [15]. The National 
Health System (NHS) provides free medical care to 99.5% 
of the Spanish population, although those persons not 
covered by the NHS can be attended at the public hospi-
tals. Private hospitals represent only a small proportion 
of all hospital admissions. Since 2005, CMBD also has a 
gradual coverage from private hospitals [16].
International Classification of Diseases, Ninth Revi-
sion, Clinical Modification (ICD-9CM), the ICD ver-
sion employed during the study period, was used for this 
purpose [17]. Registers with ICD-9 CM “malaria” and 
“malaria complicating pregnancy childbirth or the puer-
perium” codes (“084.*”; “647.4”) placed in any diagnos-
tic position were analysed. The database was cleaned to 
remove any potential duplicates of hospitalizations. Soci-
odemographic and clinical data were collected. Relevant 
malaria related co-diagnoses were also explored.
RENAVE
Surveillance on malaria is comprehensive in Spain and 
based on aggregated and case-based notification. Case 
definition includes probable (patient who meet clini-
cal criteria and with history of travel or permanence in 
an endemic area) and confirmed (+ laboratory confir-
mation by thick blood smear, detection of Plasmodium 
nucleic acid and/or a positive rapid diagnostic test). 
Regional public health authorities (autonomous regions) 
should report aggregated cases weekly and complete the 
reporting form information as soon as possible, using a 
standardized questionnaire [12]. Consistent individu-
alized malaria data is available from 2002 on (and it is 
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exhaustive at national level since 2014). Non-imported 
cases, which are notified urgently, were excluded for the 
analysis.
For each entry, socio-demographic, clinical and travel 
background information were analysed. Age was cat-
egorized in five groups: 0–15, 16–24, 25–34, 35–44 and 
≥ 45  years old. Place of birth and travel information 
were only available from RENAVE and includes place of 
birth and travel (country or continent when country is 
unknown), date and reason for travel (tourism, visiting 
friends and relatives (VFRs), work or being immigrant—
this category includes people who had spent more than 
1 year living in an endemic area, independently of their 
nationality).
Statistical analysis
The average number of hospitalizations per year was 
calculated in order to assess temporal patterns. Popula-
tion figures of the Spanish municipalities were obtained 
from the Spanish National Statistics Institute [18] and 
were used as denominators for the study period, for both 
CMBD and RENAVE data.
Frequencies and percentages were used to summarize 
CMBD and RENAVE data. Differences in proportions 
were assessed by the χ2 test and 95% confidence intervals 
(95% CI) were calculated. ANOVA was used to compare 
differences in means. Two-sided tests were used and 
p < 0.05 was considered significant.
Bivariate analyses for continent of infection, and rel-
evant related factors were performed for RENAVE data. 
Bivariate analyses preceding logistic regression models 
for preventive chemotherapy (RENAVE), fatal outcome 
(CMBD and RENAVE) and hospitalization (RENAVE) 
were also carried out. Probable cases were excluded from 
the multivariate regression analysis, which were obtained 
by using a manual backward stepwise procedure. Age and 
gender, considered biologically relevant, and all variables 
associated with each of the outcomes at the p < 0.10 level 
were included in the multivariable analysis. The major 
assumptions of logistic regression analysis (absence of 
multicollinearity and interaction among independent 
variables) were checked to be satisfied. The goodness of 
fit was assessed using Hosmer–Lemeshow statistic. The 
adjusted odds ratio (aOR) and 95% CI were computed. 
p-values less than or equal to 0.05 were considered sta-
tistically significant. Data analysis was performed using 
STATA software version 14.
Ethics statement
This study involves the use of patient data from The 
Spanish Centralized Hospital Discharge Database 
(CMBD) and the RENAVE. CMBD data are hosted by 
the Ministry of Health, Consumption and Social Welfare 
(MSCBS in Spanish). Researchers working in public and 
private institutions can request the databases by fill-
ing, signing and sending a questionnaire available at the 
MSCBS website. A signed Confidentiality Commitment 
is required in this questionnaire. All data are anonymized 
and de-identified by the MSCBS before it is provided to 
applicants. According to this Confidentiality Commit-
ment signed with the MSCBS, researchers cannot pro-
vide the data to other researchers that must request the 
data directly to the MSCBS [15]. RENAVE data are regis-
tered through the national reporting electronic platform 
(SiViEs in Spanish) and hosted by the National Centre of 
Epidemiology. The so-called “SiViEs” computer platform 
was designed for epidemiological surveillance in Spain. 
It meets all legal and technical requirements concerning 
safe access and data protection. Formal ethical approval 
is not required for routine surveillance activities in Spain.
Results
A total of 9513 hospital discharges related to malaria 
(ICD-9-CM codes 123.*) and 7421 reported cases of 
malaria (6060 imported cases with individualized data) 
were identified for the 14-year study period. The number 
of reported cases was below the number of hospitaliza-
tions during the whole study period, although the differ-
ence between both records decreased over time (Fig. 1).
The most frequent isolated species of Plasmodium in 
both databases was Plasmodium falciparum. 26.7% and 
14.7% cases were non-specified malaria in CMBD and 
RENAVE, respectively (p < 0.01) (Fig. 2).
According to CMBD records, the mean age of the 9513 
hospitalized patients was 31.9  years [interquartile range 
(IQ) = 23–41], being the 25–34 and 35–44 age groups 
the most represented. A total of 63.8% hospitalized were 
males, particularly predominating above 25  years old 
groups. There were 262 hospitalized women with preg-
nancy-associated malaria.
The majority (94.6%) of malaria patients with known 
source of admission were admitted from emergency 
rooms. 95.8% of hospitalizations were discharged at 
home, death occurring in 0.8%. The risk of fatal outcome 
increased with age (mean of 50.4 vs. 31.7 years old in exi-
tus and non-exitus, respectively; aOR: 1.05; 95% CI 1.03–
1.07). The exitus outcome was also more frequent among 
those hospitalized with mixed malaria (aOR: 4.21; 95% CI 
1.45–12.21). The hospitalization median time was 4 days 
(IQ range = 3–6), with a median cost of 3995 € (Table 1).
Most frequent related co-diagnoses were anaemia 
(20.2%, mostly iron deficiency anaemias and acquired and 
hereditary haemolytic anaemias), thrombocytopaenia 
(15.4%; ICD-9-CM codes: 287.3-5), splenomegaly (2.4%; 
ICD-9-CM code: 789.2) and hepatomegaly (1.5%; ICD-
9-CM code: 789.3). Other frequent co-diagnoses were 
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HIV (4.8%; ICD-9-CM codes: 042, V08), acute kidney 
failure/non-specified (4.2%; ICD-9-CM code: 584, 586) 
and helminthiases (3.1%; ICD-9-CM code: 120–129).
In the RENAVE, epidemiological questionnaire were 
available for 6060 out of 7421 (81.7%) reported cases of 
malaria. The 64.7% were males. The mean age was 32.6 
(IQ range = 25–41). More than 50% were between 25 and 
45 years of age. The majority were born in a country other 
than Spain (66.2%), being Africa the most frequent con-
tinent of birth (59.0%). The main place of infection was 
Africa (88.9%), particularly Equatorial Guinea (33.2%). 
Most reported cases were VFRs and immigrants (70.2%). 
Only 4% referred a correct regime of chemoprophylaxis 
(Table 2).
74.8% of reported cases had required hospitalization. 
A significant increased likelihood of hospitalization was 
Fig. 1 Imported malaria incidence rates per 100,000 population based on CMBD and RENAVE records, Spain, 2002–2015. RENAVE data is based 
in individual case reports, except for one region. In this case, the number of cases per year were replaced by aggregated data. Starting from 2014, 
RENAVE individualized data are comprehensive for the whole country
Fig. 2 Type of isolated Plasmodium, CMBD and RENAVE, Spain, 2002–2015
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observed for children under 10 years (aOR: 2.7; 95% CI 
1.9–3.9), those infected by P. vivax (4.3; 95% CI 2.1–8.7), 
mixed Plasmodium infections (aOR: 3.2; 95% CI 1.4–7.5), 
P. falciparum (aOR: 3.1; 95% CI 1.7–5.6), and Plasmo-
dium ovale (aOR= 2.3; 95% CI 1.1–5.2), being Plasmo-
dium malariae the reference category, and VFRs (1.4; 
95% CI 1.1–1.7) with respect to other travellers.
Fatal outcome was reported for 35 cases (0.6%), from 
whom 30 were due to P. falciparum and 1 to mixed P. 
falciparum and P. ovale malaria, all infected in Africa 
(unknown species in 4 cases). The risk of fatal outcome 
increased with age (aOR: 1.04; 95% CI 1.02–1.07) and for 
those born in Europe (5.4; 95% CI 1.5–20.2), indepen-
dently of the reason for travel.
In 95% of the records, the most likely continent of 
infection was supplied (Table 2). Gender distribution was 
similar for all the continents. Cases coming from Asia 
were significantly younger than those infected in other 
continents (p < 0.01). More than a half of patients infected 
in Africa were VFRs, while there was a higher proportion 
of tourists among cases coming from America and Asia 
(p < 0.01). Infections acquired in Asia and America were, 
for the greater part, caused by P. vivax (78.5% and 61.1%, 
respectively), whereas those acquired in Africa were 
mainly caused by P. falciparum (92.3%) (Table 3).
Being male and older than 15 years old were associated 
to increased risk of failure in preventive chemotherapy 
(considering failure as none or non-complete preven-
tive treatment) (Table  3). VFRs were 1.8 times more 
prompted to fail in malaria preventive chemotherapy 
than those travelling for work purposes. The risk was 
even higher for immigrants (aOR: 3.3; 95% CI 2.2–4.9). 
Malaria cases born in endemic countries were at higher 
risk of failure in preventive chemotherapy (Table 4).
Discussion
Overall, a slight increase in the incidence rates of 
imported malaria during the study period was found 
in both databases. According to the WHO, there have 
been important gains in malaria control over the past 
two decades worldwide, although this progress has 
stalled in many countries in the most recent years 
[19]. In the European Region, 45 countries reported a 
decline in imported malaria cases and deaths between 
2001 and 2010, possibly reflecting malaria control 
activities in endemic countries, an increase in the num-
ber of countries classified as malaria-free and/or and a 
possible under-reporting of cases [3]. Later on, at EU 
level the trend was upward until 2011, reduced in 2012 
and again increased since 2013 [20]. Most probably, 
the difference in imported malaria trends in Spain with 
other European countries is explained by differences in 
the architecture of the air network, historical ties (in 
fact, the 22.3% of malaria reported cases in Spain were 
born in Equatorial Guinea, a former Spanish colony, 
and highly endemic to malaria [21]), sociodemographic 
characteristics of travellers, and malaria endemicity, 
among other factors [13, 19]. On the other hand, this 
increase coincides with an increase in immigration fig-
ures in Spain, although this increase was halted in 2010 
mainly due to the economic crisis [22], which would 
not explain the increase in reported cases and hospi-
talizations in the last years of study. Nevertheless, it 
should be taken into account that African immigrants’ 
figures remained more or less constant during the eco-
nomic crisis [22, 23].
The comparison of compulsory notified disease records 
with hospital records indicates a discrepancy between 
both registries, as already stated by other authors for 
other infectious diseases [24, 25]. Moreover, if it is 
assumed that not all malaria cases require hospitaliza-
tion (74.8% according to RENAVE figures), then the total 
Table 1 Sociodemographic and  clinical characteristics 




 Male 6064 (63.8)
 Female 3442 (36.2)
Age‑groups (years)
 < 15 1643 (17.3)
 15–24 991 (10.4)
 25–34 2739 (28.8)
 35–44 2329 (24.5)
 ≥ 45 1810 19)
Type of admission
 Urgent 8998 (94.6)
 Programmed 507 (5.3)
 Others/unknown 8 (0.1)
Type of discharge
 Home 9113 (95.8)
 Transfer 186 (2)
 Voluntary discharge 110 (1.2)
 Others/unknown 24 (0.3)
 Exitus 80 (0.8)
Hospitalization time
 < 1 week 7154 (75.2)
 ≥ 1 week 2359 (24.8)
Mean Median (IQ range)
Age (years) 31.9 33 (23–41)
Hospitalization time (days) 5.9 4 (3–6)
Hospitalization cost (euro) 4149.3 3994.9 (3062–4296)
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number of malaria cases occurring in Spain is even 
higher. Difficulties in reporting of imported malaria do 
not apply to Spain alone. Comparison of notified cases 
with hospital records have indicated a clear discrepancy 
in several countries [26, 27]. Nevertheless, this com-
parison should be read with caution, as the number of 
hospitalized malaria cases might be overrated due to re-
admissions and/or misclassification.
Among all malaria cases, the most frequent diagnosis 
was P. falciparum. The high prevalence of P. falciparum 
is in accordance with its well-documented relative viru-
lence, the global prevalence of this species and also with 
other reports of imported malaria, mainly in patients 
returning from sub-Saharan Africa [1, 2, 28]. In the UK, 
this species accounted for about 70% of cases notified 
in 2011, whereas 25% of cases were due to P. vivax [29, 
30]. In Spain, the % of imported cases due to P. vivax was 
quite lower, probably due to differences in travel destina-
tions and immigrants’ country of origin. On the other 
hand, a worthy of consideration number of reported 
cases and related hospitalizations miss microbiological 
information. An improvement in using complementary 
information from laboratory based surveillance system 
may resolve this problem as well as improve the surveil-
lance performance.
In both databases, the distribution by gender and age 
group was similar. The proportion of malaria-related 
hospitalizations and case reporting was higher for males 
than females. Major risk of malaria among male travellers 
has been well documented [31]. Compared with women, 
men seem to be less likely to seek pre-travel advice, to 
adhere to appropriate personal vector avoidance and 
chemoprophylaxis, suffer more mosquito bites, and 
exhibit other high-risk behaviours [27, 32]. In fact, in this 
study the risk of failure in preventive chemotherapy was 
higher in males, result that support these hypotheses. 
The age distribution of malaria cases, which may reflect 
the age distribution of international travellers and immi-
grants or expatriates from endemic areas, is also consist-
ent with previous reports [6, 28].




 Male 3923 (64.7)
 Female 2106 (34.8)
 Unknown 31 (0.5)
Age‑groups (years)
 < 15 865 (14.3)
 15–24 596 (9.8)
 25–34 1791 (29.6)
 35–44 1612 (26.6)
 ≥ 45 1148 (18.9)
 Unknown 48 (0.8)
Classification
 Confirmed 5850 (96.5)
 Probable 210 (3.5)
Hospitalization
 No 815 (13.5)
 Yes 4543 (74.8)
 Unknown 702 (11.6)
Exitus
 No 3872 (63.9)
 Yes 35 (0.6)
 Unknown 2153 (35.5)
Country of residence
 Spain 3972 (65.6)
 Other 365 (6.0)
 Unknown 1723 (28.4)
Place of birth
 Spain 1216 (20.1)
 Other 4010 (66.2)
 Unknown 834 (13.8)
Continent of birth
 Africaa 3576 (59.0)
 America 150 (2.5)
 Asia 121 (2.0)
 Oceania 5 (0.1)
 Europe 1341 (22.1)
 Unknown 867 (14.3)
Travel reason
 VFRs 2770 (45.7)
 Immigrant 1482 (24.5)
 Tourism 610 (10.1)
 Work 695 (11.5)
 Unknown 503 (8.3)
Place of infection
 Africab 5389 (88.9)
 America 201 (3.3)
 Asia 154 (2.5)
 Oceania 14 (0.2)




 None 3020 (49.8)
 Non complete 626 (10.3)
 Complete 243 (4.0)
 Unknown 2171 (35.8)
VFRs visiting friends and relatives
a 1349 (37.7%) from Equatorial Guinea
b 2009 (37.3%) from Equatorial Guinea
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The median hospitalization stay was below 5  days, 
and the rate of in hospital deaths and case-fatality was 
under 1%. Available treatment regimens for malaria in 
most non-endemic countries are highly effective when 
properly and promptly administered, and symptoms 
can resolve within days [33]. The risk of hospitalization 
was higher for children under 10 years, while case fatal-
ity increased with age. Young children are at a higher risk 
of acquiring malaria abroad, while complicated disease 
occur more frequently at older ages [34]. P. vivax infec-
tion resulted in an increased risk of hospitalization. P. 
vivax infection, common in tropical countries in the 
Americas, Central and Southeast Asia, and Oceania [35], 
usually leads to milder disease and relapses. However, 
Table 3 Characteristics of reported cases by continent of infection, RENAVE, Spain 2002–2015
Variables Africa (n = 5389) America (n = 201) Asia (n = 154) Oceania (n = 14) p value
n % n % n % n %
Gender
 Male 3502 65.3 122 61.0 103 66.9 9 64.3 NS
 Female 1860 34.7 78 39.0 51 33.1 5 35.7
Age group (years)
 < 15 781 14.6 9 4.5 31 20.4 0 0.0 < 0.001
 15–24 504 9.4 32 16 28 18.4 1 7.1
 25–34 1566 29.2 82 41 46 30.3 3 21.4
 35–44 1475 27.5 42 21 23 15.1 7 50.0
 ≥ 45 1030 19.2 35 17.5 24 15.8 3 21.4
Continent of birth
 Africa 3571 74.1 0 0.0 2 1.4 0 0.0 < 0.001
 America 43 0.9 105 57.1 0 0.0 1 10.0
 Asia 27 0.6 1 0.5 88 62.9 0 0.0
 Oceania 3 0.1 0 0.0 0 0.0 2 20.0
 Europe 1178 24.4 78 42.4 50 35.7 7 70.0
Reason for travel or stay
 Immigrant 1360 26.4 64 32.8 42 30.2 3 25.0 < 0.001
 Work 654 12.7 19 9.7 10 7.2 3 25.0
 Tourism 494 9.6 67 34.4 34 24.5 5 41.7
 VFRs 2642 51.3 45 23.1 53 38.1 1 8.3
Chemoprophylaxis
 None 3790 77.9 113 83.9 95 89.0 2 37.5 < 0.001
 Non complete 589 15.5 18 10.2 11 7.6 3 25.0
 Complete 226 6.6 7 5.9 4 3.4 3 37.5
Plasmodium species
 P. falciparum 4374 92.3 55 34.0 20 14.8 5 45.5 < 0.001
 P. vivax 92 1.9 99 61.1 106 78.5 5 45.5
 P. ovale 102 2.2 0 0.0 5 3.7 1 9.1
 P. malariae 57 1.2 3 1.9 3 2.2 0 0.0
 Mixed 112 2.4 5 3.1 1 0.7 0 0.0
Hospitalization
 No 736 15.0 28 15.5 12 8.3 0 0.0 NS (p = 0.076)
 Yes 4180 85.0 153 84.5 132 91.7 11 100.0
in recent years, many cases of severe malaria have been 
reported in P. vivax and P. knowlesi malaria. This seems 
to be related to travellers’ non-immune status, no anti-
malarial prophylaxis intake (as travellers are less aware of 
malaria risk in these areas), delay in treatment, and sever-
ity of the illness at admission of travelers [36]. In fact, 
in this study the proportion of tourists among travellers 
returning from P. vivax endemic countries was higher 
than from other continents.
Death risk was higher among cases with mix infections 
and those infected with P. falciparum, which is consistent 
with the literature [1, 3, 37]. Interestingly, case fatality was 
higher for those born in Europe (5.4; 95% CI 1.5–20.2), 
independently of the reason for travel. It is known that 
Page 8 of 11Herrador et al. Malar J          (2019) 18:230 
malaria partial immunity in VFRs wanes with time result-
ing, especially after 12  years, in a more serious malaria 
clinical presentation [6, 38]. Thus, it could have been 
expected that this group showed the highest fatality rate. 
Nevertheless, it should be taken into account that the 
overall fatality rate was fairly low for meaningful analysis.
More than a half reported cases were born in Africa, 
and travellers, VFRs and immigrants accounted for the 
majority of imported malaria cases, as documented 
in several studies [28, 39]. Moreover, VFRs were less 
likely to report the use of any chemoprophylaxis. VFRs 
and immigrants from endemic countries are high risk 
groups for malaria due to their behavioral patterns and 
for geographical reason. The risk of infection vary, and is 
a function of several factors, including: the transmission 
intensity of the origin location; the activities undertaken 
in their visits; and prophylaxis availability and adherence 
[4, 40]. Also importantly, these individuals may perceive 
themselves to be immune or at low risk, and may forego 
malaria prevention measures [27].
Malaria cases from Asia were significantly younger 
than those infected in other continents. A possible expla-
nation might be that Asian migrants travel with their 
family members more frequently than migrants com-
ing from Africa [41]. Moreover, there was a higher % of 
tourists among cases coming from America and Asia. 
Although there is no risk of malaria in many tourist des-
tinations in south-east Asia, the Caribbean and Latin 
America [1], malaria is still prevalent in other Southeast 
Asian and Latin American areas where large numbers of 
backpackers visit each year [3]. Furthermore, these trav-
ellers’ risk perception might be low and thus affect the 
pre-travel health-seeking practices [42].
Overall, more than 60% of imported cases referred 
incomplete or none chemoprophylaxis. This % was par-
ticularly high among VFRs and migrants. According to 
the CDC, failure of prophylaxis may occur for at least 
three reasons. First, travellers may not seek or follow 
advice, or may receive inaccurate advice. Second, travel-
lers may forget or not completely understand chemopro-
phylactic advice, or they may even be advised by peers 
not to use chemoprophylaxis. Third, general physicians 
infrequently provide pre-travel advice to patients and 
may not be aware of the current recommendations [43]. 
It is agreed that VFRs and immigrants are malaria risk 
groups requiring special attention [2, 27, 31]. Particu-
larly, VFRs seem to be less inclined than other travellers 
to get pre-travel advice and to use chemoprophylaxis 
against malaria [13]. According to Scolari et  al. in Italy, 
around 80% of migrants and VFRs do not have adequate 
information and do not take preventive measures dur-
ing travel, although they are aware of the malaria risk in 
their origin countries [44]. In a recent qualitative study, 
it was observed that an important determinant that 
explained preventive behavior was the opinion that cur-
ing malaria is easier than using preventive tablets [45]. 
Moreover, recommendations for malaria chemoprophy-
laxis may often fail to address the cultural, social and 
economic needs of VFRs [46]. Finally, several studies in 
Spain found that migrants use health services differently 
from natives: they attend more frequently general prac-
titioner (GP) practices and emergency rooms, especially 
those migrants from low-income countries [47, 48]. This 
problem has been recently approached in UK, by approv-
ing the switch of anti-malarial from a prescription-only 
medicine to a pharmacy medicine [49]. In Spain, malaria 
chemoprophylaxis is considered to be as a medical physi-
cian competence. This measure may not be appropriate in 
this country for the following reasons (among others): (a) 
anti-malarial prescription might be accurately assessed if 
it is necessary or not, depending on the destination and 
type of travel. According to the traveller’s profile and his/
her medical conditions, the appropriate drug and regi-
men would be decided. Otherwise, it might not be secure 
for travellers, creating scope to hasten the problem of 
antimicrobial immunity; (b) it may pose a challenge for 
the worldwide increase in antimicrobial resistance, and 
(c) Spanish pharmacists may not be prepared to give this 
kind of health advice, i.e. they do not have quick access to 
the latest information on what antimalarial is suitable to 
a given geography at a given time. In Spain, more suitable 
alternatives to improve malaria prevention in travellers 
may be: to reduce the price of prescribed anti-malarials; 
to make health services for immigrants and travellers 
(particularly VFRs) more readily available and adapted 
Table 4 Risk factors for failure in preventive chemotherapy, 
RENAVE, Spain 2002–2015
a Countries endemic for malaria by 2015 [1]
Variables aOR 95% CI p value
Age group (ref.: < 15 years) (years)
 15–24 1.1 1.1–2.4 0.009
 25–34 1.6 1.2–2.3 0.001
 35–44 1.8 1.3–2.4 < 0.001
 45+ 1.5 1.1–2.1 0.011
Gender (ref.: female)
 Male 1.3 1.1–1.6 0.002
Reason for travel or stay (ref.: work)
 Immigrant 3.3 2.2–4.9 < 0.001
 Tourism 1.4 1.0–1.9 0.040
 VFR 1.8 1.3–2.5 < 0.001
Born in malaria endemic country (ref.: no)a
 Yes 2.3 1.7–3.0 < 0.001
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to these risk groups; and to improve and expand the pre-
travel advice at primary health care level.
Limitations and conclusions
This study has several limitations. Despite that two offi-
cial databases (RENAVE and CMBD) were analysed, 
must probably the real burden of imported malaria 
in Spain is still underestimated. On one hand, hospi-
tal discharge records do not include cases managed in 
outpatient settings or asymptomatic cases, thus hospi-
tal records are still underestimating the real burden of 
malaria. Moreover, CMBD remains dependent by the 
population’s health seeking behavior and healthcare 
accessibility [50]. On the other hand, underreport-
ing of cases by national surveillance systems is com-
mon issue in Europe [4, 6]. It is important to address 
the constraints leading to underreporting, namely pro-
viding education and feedback to relevant health care 
workers on the importance of the notification process. 
Other limitation is the lack of denominator (overall 
number of travellers by origin and destination). Never-
theless, CMBD and RENAVE data are representative of 
the imported cases of Spain. Furthermore, it is the first 
time that both databases are analysed together in this 
particular issue.
Both analysed databases miss relevant information, 
such as personal and travel information, which may 
be useful to further explore and explain the raised 
hypotheses. These calls for the need to undertake fur-
ther (qualitative and quantitative) investigations not 
only to substantiate these results but also to check new 
hypothesis which may have emerged.
This study confirms that the risk of imported malaria 
is higher in travellers from Africa, especially immi-
grants and VFRs, and that male and patients at the 
extremes of age constitute groups with increased risks. 
This study results also points that failure in preventive 
chemotherapy is still too common among imported 
malaria cases, particularly among those groups. All 
pre-travel advice needs to be individualized for each 
traveller, based on the traveller cultural background, 
exact travel route, season, and type of travel.
Finally, data on the features of imported cases can 
also provide valuable information about both the epi-
demiology of malaria in endemic regions, and on how 
malaria moves around the world. Moreover, with 
Anopheles vectors still present, imported cases can also 
cause secondary transmission in Spain, although the 
chances of resumption of endemic transmission are 
very small. This is mainly due to the fact that circulating 
anopheles in Spain are only competent for P. vivax [8]. 
Nevertheless, other Anopheles species might be rein-
troduced in the future. Thus, it should be highlighted 
the importance of vector and human cases surveillance 
for prevention of introduced malaria in non-endemic 
regions to avoid reemergence situations, as it recently 
occurred in Greece [7].
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